Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Mitsui Dm Sugar Co. Ltd. is currently engaged in the Biotechnology & Pharmaceuticals technology area with 1 pending office action. This matter is being reviewed by 1 distinct examiner, GOTFREDSON, GAREN. The prosecution is localized within 1 distinct art unit, reflecting a focused approach to its intellectual property. This concentration suggests that the company's current legal efforts are directed toward a specific technical niche within its field.
The busiest examiner, GOTFREDSON, GAREN, is assigned 1 pending office action, which represents the total active volume for the company. Because there is only 1 distinct examiner and 1 distinct art unit, the company's current prosecution efforts are entirely centralized. This eliminates the need for managing multiple examiner relationships or navigating different art unit norms, allowing for a highly efficient response strategy.
The 1 pending office action serves as the primary focus for the company's current USPTO strategy. With 1 distinct examiner involved, the company can apply a targeted approach to its patent goals. This structure provides a clear and direct path for the outstanding matter currently under review, as the 1 distinct art unit classification ensures that the technical arguments remain within a unified administrative framework.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GOTFREDSON, GAREN | 1 | 40.0% | +28.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18757769 | Anti-Obesity Agent, Anti-Dementia Agent, Deodorant, Anti-Aging Agent, Anti-Glycation Agent, Anti-Type I Allergy Agent, Hypotensive Agent, Flavor Improving Agent, Muscle Enhancing Agent, and Bone Metabolism Improving Agent | GOTFREDSON, GAREN | 12d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18757769 | Anti-Obesity Agent, Anti-Dementia Agent, Deodorant, Anti-Aging Agent, Anti-Glycation Agent, Anti-Type I Allergy Agent, Hypotensive Agent, Flavor Improving Agent, Muscle Enhancing Agent, and Bone Metabolism Improving Agent | GOTFREDSON, GAREN | 12d |
| Art Unit | Apps |
|---|---|
| 1619 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18757769 | Anti-Obesity Agent, Anti-Dementia Agent, Deodorant, Anti-Aging Agent, Anti-Glycation Agent, Anti-Type I Allergy Agent, Hypotensive Agent, Flavor Improving Agent, Muscle Enhancing Agent, and Bone Metabolism Improving Agent | GOTFREDSON, GAREN | 1619 | §102§103Other | Final Rejection | 12d | Pending | Jun 28, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial